Avid Bioservices, Inc. (CDMO) Q3 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings report reveals significant financial declines, including increased net losses and reduced cash reserves, despite a strong bookings backlog. The Q&A highlighted management's optimism but lacked specific guidance details, raising concerns. The company's market strategy, expenses, and financial health appear weak, with operating losses and declining margins. While there are some positive elements, like backlog growth and potential market opportunities, the overall sentiment is negative due to financial challenges and management's reluctance to provide clear guidance.
Key Financial Performance
Revenues for Q3 2024 $33.8 million, an 11% decrease from $38 million in Q3 2023 due to fewer manufacturing runs and a reduction in process development services from early-stage customers.
Revenues for the first nine months of fiscal 2024 $96.9 million, a decrease of approximately 11% compared to $109.5 million in the same prior year period, attributed to fewer manufacturing runs and a reduction in process development services.
Gross profit for Q3 2024 $2.4 million or 7% gross margin, down from $9.8 million or 26% gross margin in Q3 2023, primarily driven by fewer manufacturing runs and increased costs related to expansions.
Gross profit for the first nine months of fiscal 2024 $1.8 million or 2% gross margin, compared to $23.1 million or 21% gross margin for the same period in fiscal 2023, impacted by fewer manufacturing runs, a terminated project, and increased costs.
SG&A expenses for Q3 2024 $6.4 million, a decrease of 10% from $7.1 million in Q3 2023, due to decreases in compensation and benefit-related expenses and consulting fees.
SG&A expenses for the first nine months of fiscal 2024 $19.2 million, a decrease of approximately 6% compared to $20.3 million in the same prior year period, attributed to reduced compensation and consulting fees.
Operating loss for Q3 2024 $4 million, compared to operating income of $2.7 million in Q3 2023, driven by a decrease in gross profit.
Operating loss for the first nine months of fiscal 2024 $17.4 million, compared to operating income of $2.8 million for the same period in fiscal 2023, primarily due to decreased gross profit.
Net loss for Q3 2024 $6 million or $0.09 per share, compared to a net loss of $0.2 million or $0 per share in Q3 2023.
Net loss for the first nine months of fiscal 2024 $17.6 million or $0.28 per share, compared to net income of approximately $0.6 million or $0.01 per share during the same prior year period.
Cash and cash equivalents as of January 31, 2024 $30.7 million, down from $38.5 million on April 30, 2023.
Backlog at the end of Q3 2024 $206 million, an increase of 17% compared to $176 million at the end of Q3 2023, driven by strong bookings of $41 million during the period.
Operating Highlights
New Facility Opening: Avid opened a new cell and gene therapy (CGT) facility, completing a three-year expansion program that enhances service offerings and revenue-generating capacity.
Project Agreements: Signed multiple new project agreements worth $41 million, contributing to a record backlog of $206 million.
Market Positioning: The company is better positioned to address the needs of large pharma customers with expanded capabilities.
Pipeline Improvement: Incremental improvement in early-stage project bookings, indicating a potential recovery in the biotech financing environment.
Operational Efficiency: Expecting strengthening cash flow and margins as capital expenditures cease and operating leverage from new facilities is realized.
Strategic Shift: Avid's strategic plan focuses on elevating the organization to service multiple CDMO markets, targeting late-stage programs for growth.
Risk or Challenges
Debt Management Risk: The company faced a default stemming from a technical requirement related to legend removal, leading to the acceleration of convertible senior notes due 2026. This necessitated a refinancing effort, which could pose risks if market conditions change.
Revenue Decline Risk: Revenues for Q3 2024 decreased by 11% compared to the same prior year period, attributed to fewer manufacturing runs and reduced process development services from early-stage customers.
Operational Challenges: The company experienced a significant decrease in gross profit margins, down to 7% from 26% in the same quarter last year, primarily due to fewer manufacturing runs and increased costs related to expansions.
Customer Insolvency Risk: A terminated project related to the insolvency of one of the company’s smaller customers impacted revenue, highlighting the risk associated with customer financial stability.
Market Environment Risk: The company noted a challenging financing environment for biotech firms, which has historically affected early-stage project bookings, although there are signs of improvement.
Regulatory Approval Risk: The pipeline is weighted towards later-stage programs, which take longer to execute and may delay revenue recognition, posing risks associated with regulatory approvals.
Cash Flow Risk: Cash and cash equivalents decreased from $38.5 million to $30.7 million, indicating potential liquidity challenges if revenues do not stabilize.
Guidance & Outlook
New Project Agreements: During the third quarter, Avid signed multiple new project agreements totaling $41 million, resulting in a record backlog of $206 million.
Expansion Program: The completion of the new cell and gene therapy facility marked the final step in a three-year expansion program, enhancing service offerings and revenue-generating capacity.
Pipeline Improvement: There was an increase in early-stage project bookings, indicating a potential improvement in the financing environment for biotechs.
Operational Leverage: The company expects strengthening cash flow and margins as capital expenditures cease and benefits from the new facilities are realized.
Regulatory Approvals: One high-value program in the late-stage pipeline has already achieved FDA approval, with others advancing through the approval process.
Revenue Expectations: Avid anticipates a strong fourth quarter, projecting that second half 2024 revenues will be among the best in the company’s history.
Financial Stability: The refinancing of convertible notes extended maturity to 2029, providing stability to focus on filling new capacity.
Future Margins: While current investments have impacted margins, growing utilization of new capacity is expected to strengthen margins in the near term.
Long-term Growth: Avid aims to achieve consistent growth and sustainable profitability, positioning itself as a supplier of choice in the industry.
Shareholder Return Plan
Convertible Senior Notes Offering: Closed an offering of $160 million aggregate principal amount of 7% convertible senior notes due on March 1, 2029. Used approximately $146 million of the net proceeds to repurchase and repay 2026 notes.
Key Q&A
Earnings Word Cloud
CDMO Transcript
The earnings call reveals a mixed outlook. Financial performance shows modest revenue growth and improved gross margin, but rising SG&A expenses and a widened net loss raise concerns. The Q&A section highlights uncertainties in backlog burn rate and large pharma strategy. While new project agreements and capacity expansion are positive, financial instability and competition pose risks. The lack of a share repurchase program and unclear management responses further contribute to a neutral sentiment. Despite optimistic guidance and infrastructure investments, the absence of strong catalysts limits positive sentiment.
The earnings call summary and Q&A indicate a challenging financial situation with a significant increase in net loss due to income tax provisions. Despite positive developments like new project agreements and expansion, the lack of clear guidance and management's vague responses in the Q&A raise concerns. The market strategy and shareholder return plan seem weak, with no significant positive catalysts. Adjusted for these insights, the overall sentiment is negative, likely leading to a stock price decrease of -2% to -8% over the next two weeks.
The earnings report reveals significant financial declines, including increased net losses and reduced cash reserves, despite a strong bookings backlog. The Q&A highlighted management's optimism but lacked specific guidance details, raising concerns. The company's market strategy, expenses, and financial health appear weak, with operating losses and declining margins. While there are some positive elements, like backlog growth and potential market opportunities, the overall sentiment is negative due to financial challenges and management's reluctance to provide clear guidance.
The earnings call revealed significant financial challenges, including a sharp decline in gross margins, increased net losses, and negative adjusted EBITDA. Despite a record backlog, revenue and margin issues persist, with management providing vague responses on revenue timelines. The market is likely to react negatively due to these financial setbacks and uncertainties, compounded by management's unclear guidance. However, the increased backlog and cash reserves may provide some cushion, preventing a strong negative impact.
CDMO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
